+ 0.17
+ 0.05%

UCSF Launches New Psychedelic Research Division

April 24, 2021 1:08 pm
Share to Linkedin Share to Twitter Share to Facebook Share to Print License More
UCSF Launches New Psychedelic Research Division

This article by Jennifer Walker-Journey was originally published on Psychedelic Spotlight, and appears here with permission.

The University of California, San Francisco (UCSF) is creating a Neuroscape Psychedelics Division, a multidisciplinary research center to bridge the gap between neuroscience and technology. The division, funded by $6.4 million in private donations, will take a translational research approach to integrate cutting-edge neuroscience technology with psychedelics treatment. As part of that effort, the division will be conducting a Multidisciplinary Association for Psychedelic Studies (MAPS)-supported phase III clinical trial investigating MDMA for the treatment of post-traumatic stress disorder (PTSD). 

“Our generous funders are making possible a major leap forward in generating evidence of clinical efficacy and safety for individuals using psychedelics to treat a broad range of mental health conditions, including depression, anxiety, PTSD, and addiction,” says Adam Gazzaley, Executive Director of Neuroscape. “At Neuroscape, we have taken a neuroscience-based, closed-loop approach to creating experiential medicine, including the first FDA-cleared video game as a medical therapeutic. We are excited to apply this same approach to understanding how we can deliver psychedelic treatments in a more personalized and precisely-targeted manner.”

UCSF’s Neuroscape Psychedelics Division will focus on “set and setting,” the contextual elements that shape patient experience, including conditions that exist prior to, during, and after treatments. Throughout these stages, study participants’’ neural and physiological status will be recorded, while environmental conditions, such as music, light, and scent, are adjusted accordingly.

“This research will allow us to understand if a particular treatment is well-suited to an individual, assessing in real-time how an experience is unfolding. We aim to dynamically adjust key contextual elements in a way that guides patients toward an optimal experience — thus maximizing long-term, sustainable positive benefits,” says Jennifer Mitchell, Associate Professor of Neurology and Psychiatry at UCSF. Mitchell will be leading the university’s clinical trials on MDMA for PTSD.

Read the original Article on Psychedelic Spotlight.

Benzinga's Related Links: 

For the latest in financial news, exclusive stories, memes follow Benzinga on Twitter, Facebook & Instagram. For the best interviews, stock market talk & videos, subscribe to our YouTube channel.


Cannabis Markets

Related Articles

Cannabis Industry Chart Of The Week: The Cost Of Cannabis Debt - The Gap Grows

As debt raises continue to increase for large and smaller operators, Viridian has calculated an “effective cost” analysis to truly arrive at cost of capital for borrowers. Our calculation explicitly values all embedded options including convertibility and any warrant coverage. read more

Living In the Age Of Cannabis Delivery On Demand

This article was originally published on Cannabis & Tech Today, and appears here with permission. Many would argue 2020 has been the most stressful year in a generation. read more

The Clinical Trial Process For Psychedelics And Beyond, Explained

This article was originally published on Microdose Psychedelic Insights and appears here with permission. read more

Oklahoma Cannabis Market Report: What You Need To Know

This article was originally published on Confident Cannabis, and appears here with permission. read more